Effect of naloxone on plasma insulin, insulin-like growth factor I, and its binding protein 1 in patients with polycystic ovarian disease.
Insulin and insulin-like growth factors (IGFs) stimulate ovarian steroidogenesis, and hyperinsulinemia is often accompanied by hyperandrogenemia in women with polycystic ovarian disease (PCOD). Because opioid peptides are involved in the regulation of insulin secretion, we studied the effect of naloxone-induced opiate receptor blockade on the circulating levels of insulin, IGF-I, and IGF binding protein 1 (IGFBP-1) in 13 nonobese and 7 obese PCOD patients and in 6 healthy subjects. In obese PCOD patients, the mean basal insulin concentration was significantly higher and the IGFBP-1 concentration lower than in nonobese PCOD patients. Plasma IGF-I levels were elevated both in obese and nonobese PCOD patients. After an intravenous bolus of 10 mg naloxone, no significant changes were found in the circulating insulin or IGF-I levels, whereas IGFBP-1 levels decreased in nonobese PCOD patients and remained low in obese PCOD patients. No significant decrease was found in healthy subjects. These results suggest that, in addition to insulin, endogenous opioids are involved in the regulation of serum IGFBP-1 level.
Laatikainen
T
T
Department of Obstetrics and Gynecology, University of Helsinki, Finland.
Anttila
L
L
Suikkari
A M
AM
Ruutiainen
K
K
Erkkola
R
R
Seppälä
M
M
D000293:Adolescent; D000328:Adult; D002352:Carrier Proteins / Q000097:blood*; D004723:Endorphins / Q000008:administration & dosage / Q000378:metabolism / Q000502:physiology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood*; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology*; D010053:Ovary / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000473:pathology; D011957:Receptors, Opioid / Q000378:metabolism; D013002:Somatomedins / Q000032:analysis*
D002352:Carrier Proteins; D004723:Endorphins; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D011957:Receptors, Opioid; D013002:Somatomedins; D009270:Naloxone; D007334:Insulin-Like Growth Factor I